I read with interest the perspective on the emerging role of Sildenafil in
neonatology [1]. I was disappointed with the authors’ statement, "We could
not find any Indian data or case report on use of sildenafil in PPHN". I
have published my use of sildenafil in two term neonates with PPHN which
was missed by authors [2]. I also feel disappointed by the lack of studies
emerging from Indian subcontinent on use of sildenafil in neonates
(especially with PPHN) as my belief is that developing countries are in a
unique situation to conduct such research [3]. In developed countries,
ethical dilemmas will arise as inhaled nitric oxide has become standard
treatment for PPHN in term neonates.
I completely agree with Malik and Nagpal that all
experiences with sildenafil in neonates must continue to be monitored and
reported. However, it reads like a wishful superficial statement with no
suggestions of who is going to monitor and report and how. In India,
almost three-quarters of pediatricians are in private practice and it is
very likely that this cohort is more likely to use this drug as an off
label use. Doctors using it will be highly uncomfortable reporting it if
they meet out with adverse events or mortality. This would be because of
lack of access to Institutional ethics committees or ethicists for
consultations, reliance on their conscience and potential for causing
controversy. The journals will be critical and hesitant to publish due to
lack of evidence and ethical concerns.
Sildenafil is a Schedule 4 drug in Australia meaning it
is a prescription only drug. However, for indications other than where it
is approved, hospitals seek approval of drug committees comprising experts
in field and consultation with ethicists if such dilemmas arise. For
medications not available in Australia, provisions exist using Special
Access Scheme of Therapeutic Good Administration, for procuring and using
off-lable drugs [4]. This results in monitoring of the drug and outcomes.
Off label use of drugs including sildenafil is an
unfortunate reality in neonatology [5]. Mechanisms and regulatory bodies
on regional basis for monitoring this needs to be developed to ensure safe
neonates in myriad neonatal units mushrooming in India, especially in the
private sector.
References
1. Malik M, Nagpal R. Emerging role of sildenafil in
neonatology. Indian Pediatr. 2011;48:11-3.
2. Garg P. Oral sildenafil for PPHN in neonates:
selction of patients remains a dilemma? J Coll Physicians Surg Pak.
2008;18:132-3.
3. Juliana AE, Abbad FC. Severe persistent PPHN of the
newborn in a setting where limited resources exclude the use of inhaled
nitric oxide: successful treatment with sildenafil. Eur J Pediatr.
2005;164:626-9.
4. Therapeutic Good Administration. Special Access
Scheme. Available from: http://www.tga.gov.au/hp/sas.htm. Accessed January
7, 2011.
5. Dessi A, Salemi C, Fanos V, Cuzzolin L. Drug
treatments in a neonatal setting: focus on the off-label use in the first
months of life. Pharm World Sci. 2010;32:120-4.